Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues.

Prakash S. Masand, Thomas L. Schwartz, Xiaohong Wang, Daniel J. Kuhles, Sanjay Gupta, Bhushan Agharkar, Jacob Manjooran, Ahmad Hameed, William Hardoby, Subhdeep Virk, Bradford Frank

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The goal of this study was to ascertain why patients are maintained on conventional antipsychotics and whether the risks/benefits and alternative treatments with novel antipsychotics are discussed with these patients. We reviewed the charts of 117 outpatients maintained on conventional antipsychotics at three New York hospitals: Hutchings Psychiatric Center (HPC), Syracuse Veterans Affairs Medical Center (SVA), and the Continuing Day Treatment Program (CDT). The major reasons for maintaining patients on conventional antipsychotics were good response (50%), patient choice (45%), and physician choice (36%). Despite the high incidence of tardive dyskinesia at all three hospitals (range: 12%-50%), physicians often did not discuss the risks/benefits of continuing conventional antipsychotics with the patients. The treating psychiatrist discussed alternative treatments with 37% of patients at SVA, 58% at HPC, and 68% at CDT (P = 0.066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes.

Original languageEnglish (US)
Pages (from-to)484-487
Number of pages4
JournalAmerican journal of therapeutics
Volume9
Issue number6
DOIs
StatePublished - Jan 1 2002

Fingerprint

Informed Consent
Antipsychotic Agents
Therapeutics
Psychiatry
Physicians
Psychiatric Hospitals
Veterans
Outpatients
Incidence

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Masand, P. S., Schwartz, T. L., Wang, X., Kuhles, D. J., Gupta, S., Agharkar, B., ... Frank, B. (2002). Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues. American journal of therapeutics, 9(6), 484-487. https://doi.org/10.1097/00045391-200211000-00004
Masand, Prakash S. ; Schwartz, Thomas L. ; Wang, Xiaohong ; Kuhles, Daniel J. ; Gupta, Sanjay ; Agharkar, Bhushan ; Manjooran, Jacob ; Hameed, Ahmad ; Hardoby, William ; Virk, Subhdeep ; Frank, Bradford. / Prescribing conventional antipsychotics in the era of novel antipsychotics : informed consent issues. In: American journal of therapeutics. 2002 ; Vol. 9, No. 6. pp. 484-487.
@article{9bafe09edc6f4c4f870625afec02e112,
title = "Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues.",
abstract = "The goal of this study was to ascertain why patients are maintained on conventional antipsychotics and whether the risks/benefits and alternative treatments with novel antipsychotics are discussed with these patients. We reviewed the charts of 117 outpatients maintained on conventional antipsychotics at three New York hospitals: Hutchings Psychiatric Center (HPC), Syracuse Veterans Affairs Medical Center (SVA), and the Continuing Day Treatment Program (CDT). The major reasons for maintaining patients on conventional antipsychotics were good response (50{\%}), patient choice (45{\%}), and physician choice (36{\%}). Despite the high incidence of tardive dyskinesia at all three hospitals (range: 12{\%}-50{\%}), physicians often did not discuss the risks/benefits of continuing conventional antipsychotics with the patients. The treating psychiatrist discussed alternative treatments with 37{\%} of patients at SVA, 58{\%} at HPC, and 68{\%} at CDT (P = 0.066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes.",
author = "Masand, {Prakash S.} and Schwartz, {Thomas L.} and Xiaohong Wang and Kuhles, {Daniel J.} and Sanjay Gupta and Bhushan Agharkar and Jacob Manjooran and Ahmad Hameed and William Hardoby and Subhdeep Virk and Bradford Frank",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00045391-200211000-00004",
language = "English (US)",
volume = "9",
pages = "484--487",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Masand, PS, Schwartz, TL, Wang, X, Kuhles, DJ, Gupta, S, Agharkar, B, Manjooran, J, Hameed, A, Hardoby, W, Virk, S & Frank, B 2002, 'Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues.', American journal of therapeutics, vol. 9, no. 6, pp. 484-487. https://doi.org/10.1097/00045391-200211000-00004

Prescribing conventional antipsychotics in the era of novel antipsychotics : informed consent issues. / Masand, Prakash S.; Schwartz, Thomas L.; Wang, Xiaohong; Kuhles, Daniel J.; Gupta, Sanjay; Agharkar, Bhushan; Manjooran, Jacob; Hameed, Ahmad; Hardoby, William; Virk, Subhdeep; Frank, Bradford.

In: American journal of therapeutics, Vol. 9, No. 6, 01.01.2002, p. 484-487.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prescribing conventional antipsychotics in the era of novel antipsychotics

T2 - informed consent issues.

AU - Masand, Prakash S.

AU - Schwartz, Thomas L.

AU - Wang, Xiaohong

AU - Kuhles, Daniel J.

AU - Gupta, Sanjay

AU - Agharkar, Bhushan

AU - Manjooran, Jacob

AU - Hameed, Ahmad

AU - Hardoby, William

AU - Virk, Subhdeep

AU - Frank, Bradford

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The goal of this study was to ascertain why patients are maintained on conventional antipsychotics and whether the risks/benefits and alternative treatments with novel antipsychotics are discussed with these patients. We reviewed the charts of 117 outpatients maintained on conventional antipsychotics at three New York hospitals: Hutchings Psychiatric Center (HPC), Syracuse Veterans Affairs Medical Center (SVA), and the Continuing Day Treatment Program (CDT). The major reasons for maintaining patients on conventional antipsychotics were good response (50%), patient choice (45%), and physician choice (36%). Despite the high incidence of tardive dyskinesia at all three hospitals (range: 12%-50%), physicians often did not discuss the risks/benefits of continuing conventional antipsychotics with the patients. The treating psychiatrist discussed alternative treatments with 37% of patients at SVA, 58% at HPC, and 68% at CDT (P = 0.066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes.

AB - The goal of this study was to ascertain why patients are maintained on conventional antipsychotics and whether the risks/benefits and alternative treatments with novel antipsychotics are discussed with these patients. We reviewed the charts of 117 outpatients maintained on conventional antipsychotics at three New York hospitals: Hutchings Psychiatric Center (HPC), Syracuse Veterans Affairs Medical Center (SVA), and the Continuing Day Treatment Program (CDT). The major reasons for maintaining patients on conventional antipsychotics were good response (50%), patient choice (45%), and physician choice (36%). Despite the high incidence of tardive dyskinesia at all three hospitals (range: 12%-50%), physicians often did not discuss the risks/benefits of continuing conventional antipsychotics with the patients. The treating psychiatrist discussed alternative treatments with 37% of patients at SVA, 58% at HPC, and 68% at CDT (P = 0.066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes.

UR - http://www.scopus.com/inward/record.url?scp=0036835170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036835170&partnerID=8YFLogxK

U2 - 10.1097/00045391-200211000-00004

DO - 10.1097/00045391-200211000-00004

M3 - Article

C2 - 12424504

AN - SCOPUS:0036835170

VL - 9

SP - 484

EP - 487

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 6

ER -